Current treatment of heart failure with reduction of left ventricular ejection fraction

References

• Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adultdsummary article. Circulation. 2005;112:1825–1852.
   Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–e239.
   PubMed Web of Science ®Google Scholar
• Aronow WS. What is the appropriate treatment of hypertension in elders? J Gerontol: Med Sci. 2002;57A:M483–M486.
   Google Scholar
• Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American college of cardiology foundation task force on clinical expert consensus documents. Developed in collaboration with the American academy of neurology, American geriatrics society, American society for preventive cardiology, American society of hypertension, American society of nephrology, association of black cardiologists, and European society of hypertension. J Am Coll Cardiol. 2011;57:2037–2114.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Treatment of older persons with hypercholesterolemia with and without cardiovascular disease. J Gerontol Med Sci. 2001;56A:M138–M145.
   Google Scholar
• Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;90:147–149.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–2934.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Elderly diabetics with peripheral arterial disease and no coronary artery disease have a higher incidence of new coronary events than elderly nondiabetics with peripheral arterial disease and prior myocardial infarction treated with statins and with no lipid-lowering drug. J Gerontol: Med Sci. 2003;58A:M573–M575.
   Google Scholar
• Sanal S, Aronow WS. Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease. J Gerontol: Med Sci. 2003;58A:M1046–M1048.
   Google Scholar
• Ghosh S, Aronow WS. Utilization of lipid-lowering drugs in elderly persons with increased serum low-density lipoprotein cholesterol associated with coronary artery disease, symptomatic peripheral arterial disease, prior stroke, or diabetes mellitus before and after an educational program on dyslipidemia treatment. J Gerontol: Med Sci. 2003;58A:M432–M435.
   Google Scholar
• Rosendorff C, Lackland DT, Allison M, et al. AHA/ACC/ASH scientific statement. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American heart association, American college of cardiology, and American society of hypertension. J Am Coll Cardiol. 2015;65:1998–2038.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Management of atrial fibrillation in the elderly. Minerva Med. 2009;100:3–24.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Exercise therapy for older persons with cardiovascular disease. Am J Geriatr Cardiol. 2001;10:245–252.
   PubMedGoogle Scholar
• Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–1195.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacologic therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J Am Coll Cardiol. 2016;68:1476–1488.
   Web of Science ®Google Scholar
• Neuberg GW, Miller AB, O’Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–38.
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435.
   PubMed Web of Science ®Google Scholar
• Cohn J, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310.
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
   PubMed Web of Science ®Google Scholar
• The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828.
   PubMed Web of Science ®Google Scholar
• Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450–1456.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669–677.
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691.
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670–1676.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol. 2001;88:1298–1300.
   PubMed Web of Science ®Google Scholar
• Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312–2318.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057.
   PubMed Web of Science ®Google Scholar
• Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351–1357.
   PubMed Web of Science ®Google Scholar
• Dries DL, Strong MH, Cooper RS, et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 2002;40:311–317.
   PubMed Web of Science ®Google Scholar
• Vanhoutte PM, Auch-schwelk W, Biondi ML, et al. Why are converting enzyme inhibitors vasodilators? Br J Clin Pharmacol. 1989;28:95S–104S.
   PubMed Web of Science ®Google Scholar
• Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983;308:800–805.
   PubMed Web of Science ®Google Scholar
• Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1994;20:1549–1555.
   Web of Science ®Google Scholar
• Boger RH, Bodeboger SM, Kramme P, et al. Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid. Br J Clin Pharmacol. 1996;42:721–727.
   PubMed Web of Science ®Google Scholar
• Evans MA, Burnett JC Jr, Redfield MM. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. J Am Coll Cardiol. 1995;25:1445–1450.
   PubMed Web of Science ®Google Scholar
• Katz SD, Radin M, Graves T, et al. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril. J Am Coll Cardiol. 1999;34:170–176.
   PubMed Web of Science ®Google Scholar
• Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997;79:115–119.
   PubMed Web of Science ®Google Scholar
• Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419–425.
   PubMed Web of Science ®Google Scholar
• Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol. 1999;33:1920–1925.
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–1581.
   PubMed Web of Science ®Google Scholar
• Lapane KL, Hume AL, Barbour MM, et al. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure? J Am Geriatr Soc. 2002;50:1198–1204.
   PubMed Web of Science ®Google Scholar
• Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153:937–942.
   PubMed Web of Science ®Google Scholar
• Jilma B, Krejcy K, Dirnberger E, et al. Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. Life Sci. 1997;60:1859–1866.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004–1010.
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trialdthe losartan heart failure survival study ELITE II. Lancet. 2000;355:1582–1587.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906.
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362:772–776.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet. 2003;362:767–771.
   PubMed Web of Science ®Google Scholar
• Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1982;247:1707–1714.
   PubMed Web of Science ®Google Scholar
• Pedersen TR. Six-year follow-up of the Norwegian multicentre study on timolol after acute myocardial infarction. N Engl J Med. 1985;313:1055–1058.
   PubMed Web of Science ®Google Scholar
• Chadda K, Goldstein S, Byington R, et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503–510.
   PubMed Web of Science ®Google Scholar
• Kennedy HL, Brooks MM, Barker AH, et al. Beta blocker therapy in the cardiac arrhythmia suppression trial. Am J Cardiol. 1994;74:674–680.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients R62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction R40%. Am J Cardiol. 1994;74:267–270.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and diabetes mellitus. Am J Cardiol. 2001;87:780–781.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol. 2001;87:1284–1286.
   PubMed Web of Science ®Google Scholar
• Furberg CD, Hawkins CM, Lichstein E. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation. 1984;69:761–765.
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355.
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007.
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in chronic heart failure. N Engl J Med. 2001;344:651–658.
   Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225.
   PubMed Web of Science ®Google Scholar
• Mann DL, Deswal A, Bozkurt B, et al. New therapeutics for chronic heart failure. Annu Rev Med. 2002;53:59–74.
   PubMed Web of Science ®Google Scholar
• Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:412–417.
   PubMed Web of Science ®Google Scholar
• Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33:572–577.
   PubMed Web of Science ®Google Scholar
• Moye L, Pfeffer M. Additional beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol. 1997;29:229–236.
   PubMed Web of Science ®Google Scholar
• Exner DV, Dries DL, Waclawiw MA, et al. Beta adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol. 1999;33:916–923.
   PubMed Web of Science ®Google Scholar
• Task Force for the Diagnosis and Treatment of Chronic Heart Failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527–1560.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJV, Krun H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a veterans administration cooperative study. N Engl J Med. 1986;314:1547–1552.
   PubMed Web of Science ®Google Scholar
• The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533.
   PubMed Web of Science ®Google Scholar
• Rich MW, McSherry F, Williford WO, et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol. 2001;38:806–813.
   PubMed Web of Science ®Google Scholar
• Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403–1411.
   PubMed Web of Science ®Google Scholar
• Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871–878.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Aban IB, Weaver MT, et al. Serum digoxin concentration and outcomes in women with heart failure: a bi-directional effect and a possible effect modification by ejection fraction. Eur J Heart Failure. 2006;8:409–419.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment? Drugs Aging. 1991;1:98–103.
   PubMedGoogle Scholar
• Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920–926.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Ascheim D, Demarco T, et al. Effects of enrasentan, a nonselective endothelin receptor antagonist in class II to III heart failure: results of the Enrasentan Cooperative Randomized (ENCOR) Evaluation. J Am Coll Cardiol. 2001;38:612.
   Google Scholar
• McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure. Part II. Circulation. 2002;105:2223–2228.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–1971.
   PubMed Web of Science ®Google Scholar
• Francis GS, Tang WHW. Vasopressin receptor antagonists. Will the “vaptans” fulfill their promise? JAMA. 2004;291:2017–2018.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Aronow WS, Mondal P, et al. Limitations of sacubitril/valsartan in the management of heart failure. Am J Therap. 2017;24:xxx–xxx.
   Google Scholar
• Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954–1961.
   PubMed Web of Science ®Google Scholar
• The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385–392.
   PubMed Web of Science ®Google Scholar
• Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52–60.
   PubMed Web of Science ®Google Scholar
• Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107–1114.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as suplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Circulation. 1997;96:856–863.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885.
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940.
   PubMed Web of Science ®Google Scholar
• Aronow WS. CRT plus ICD in congestive heart failure. Use of cardiac resynchronization therapy and an implantable cardioverter-defibrillator in heart failure patients with abnormal left ventricular dysfunction. Geriatrics. 2005;60(2):24–28.
   PubMedGoogle Scholar
• Cleland JGF, Daubert J-C, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549.
   PubMed Web of Science ®Google Scholar
• Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. The MIRACLE ICD trial. JAMA. 2003;289:2685–2694.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Saxon LA, Boehmer J, et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS, et al. Cardiac- resynchronization therapy for the prevention of heart- failure events. N Engl J Med. 2009;361:1329–1338.
   PubMed Web of Science ®Google Scholar
• Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–2395.
   PubMed Web of Science ®Google Scholar
• Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834–1843.
   PubMed Web of Science ®Google Scholar
• Brignole M, Botto G, Mont L, et al. Cardiac resynchronizaton in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011;32:2420–2429.
   PubMed Web of Science ®Google Scholar
• Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol. 2009;103:1280–1284.
   PubMed Web of Science ®Google Scholar
• Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468–1475.
   PubMed Web of Science ®Google Scholar
• Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study [abstract]. Circulation. 1993;88(supplI):I–301.
   Google Scholar
• Uretsky BF, Jessup F, Konstan MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation. 1990;82:774–780.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 1998;339:1810–1816.
   PubMed Web of Science ®Google Scholar
• Pimobendan in Congestive Heart Failure (PICO) Investigators. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996;76:223–231.
   PubMed Web of Science ®Google Scholar
• Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1–6.
   PubMed Web of Science ®Google Scholar
• Hampton JR, Van Veldhusisen DJ, Kleber FX, et al. Randomized study of effect of ibopamine on survival in patients with advanced heart failure. Lancet. 1997;349:971–977.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 2000;138:78–86.
   Web of Science ®Google Scholar
• Tariq S, Aronow WS. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci. 2015;16:29060–29068.
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial. JAMA. 2002;287:1531–1540.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Massie BM. Nesiritide and worsening of renal function. The emperor’s new clothes? Circulation. 2005;111:1459–1461.
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491.
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez PW, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.
   PubMed Web of Science ®Google Scholar
• Athanasuleas CL, Stanley AW Jr, Buckberg GD, et al. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. J Am Coll Cardiol. 2001;37:1210–1213.
   PubMed Web of Science ®Google Scholar
• Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360:1705–1717.
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–1616.
   PubMed Web of Science ®Google Scholar
• Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival i ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617–1625.
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. dysfunction. N Engl J Med. 2016;374:1511–1520.
   PubMed Web of Science ®Google Scholar
• Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for endstage heart failure. N Engl J Med. 2001;345:1435–1443.
   PubMed Web of Science ®Google Scholar
• Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–2251.
   PubMed Web of Science ®Google Scholar